Illumina (ILMN) Stock Forecast & Price Target

Illumina is viewed positively because its clinical sequencing franchise is inflecting, with clinical revenue expected to grow at a durable mid-teens rate as oncology volume expands, pricing pressures ease, and reimbursement improves. The company’s ecosystem is benefiting from multiple catalysts, including stronger MRD testing, broader tumor profiling coverage, and new NGS-based blood and multi-cancer tests, while consumables remain highly attractive with gross margins above 70% and clinical consumables already representing 65%+ of sequencing consumables revenue. Although academic demand is weaker and competition remains present, those headwinds appear manageable given Illumina’s leading cost basis, regulatory switching costs, robust NovaSeq X demand, and optionality from BioInsight and other new products that could add 1–2 points of growth accretion.

Illumina is facing a weakening fundamental setup because its recent clinical growth acceleration to 17% to 20% may not be sustainable, especially since customers are driving deflation in per-sample unit economics and the read-through from oncology demand is not 1:1. Academic demand remains subdued amid lower switching costs and stronger competitive threats, while sequencing consumables revenues ex-China in research and applied end-markets are expected to be down MSD% to HSD% for 2026, signaling broad end-market softness. China adds another headwind, with sales forecast at only ~5% of 2026 revenue versus 10% a few years ago, as Illumina remains on the unreliable entities list and faces 15 years of intensifying competition from Roche, MGI, private players, and long-read sequencing companies.